menu
    • menu
    [{"orgOrder":0,"company":"Medreg","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MRG-001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medreg \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Medreg \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"MTPS9579A","moa":"\nTryptase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CSJ117","moa":"\nTSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CSJ117","moa":"\nTSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"CSJ117","moa":"\nTSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CSJ117","moa":"\nTSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baylor Research Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Baylor Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor Research Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baylor Research Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Atuliflapon","moa":"5-LOX","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS ","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS ","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS "},{"orgOrder":0,"company":"Temple University","sponsor":"National Center for Complementary and Integrative Health | Quercegen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Quercetin","moa":"Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ National Center for Complementary and Integrative Health | Quercegen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ National Center for Complementary and Integrative Health | Quercegen Pharmaceuticals"},{"orgOrder":0,"company":"Temple University","sponsor":"National Institutes of Health | Quercegen Pharmaceuticals | National Center for Complementary and Integrative Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Quercetin","moa":"Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ National Institutes of Health | Quercegen Pharmaceuticals | National Center for Complementary and Integrative Health","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ National Institutes of Health | Quercegen Pharmaceuticals | National Center for Complementary and Integrative Health"},{"orgOrder":0,"company":"RMW Testing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RMW Testing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RMW Testing \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RMW Testing \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ BARDA"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Recombinant HUman Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAegis Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BYM338","moa":"Activin receptor type-2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Palo Biofarma","sponsor":"Scope International AG","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PBF-2897","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Palo Biofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palo Biofarma \/ Scope International AG","highestDevelopmentStatusID":"8","companyTruncated":"Palo Biofarma \/ Scope International AG"},{"orgOrder":0,"company":"Hospital de la Santa Creu i Sant Pau","sponsor":"Palo Biofarma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PBF-2897","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hospital de la Santa Creu i Sant Pau","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de la Santa Creu i Sant Pau \/ Palo Biofarma","highestDevelopmentStatusID":"8","companyTruncated":"Hospital de la Santa Creu i Sant Pau \/ Palo Biofarma"},{"orgOrder":0,"company":"Palo Biofarma","sponsor":"Hospital de la Santa Creu i Sant Pau | Hospital de Sant Pau","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PBF-2897","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Palo Biofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palo Biofarma \/ Hospital de la Santa Creu i Sant Pau | Hospital de Sant Pau","highestDevelopmentStatusID":"8","companyTruncated":"Palo Biofarma \/ Hospital de la Santa Creu i Sant Pau | Hospital de Sant Pau"},{"orgOrder":0,"company":"Palo Biofarma","sponsor":"Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"PBF-2897","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Palo Biofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palo Biofarma \/ Pivotal S.L.","highestDevelopmentStatusID":"8","companyTruncated":"Palo Biofarma \/ Pivotal S.L."},{"orgOrder":0,"company":"Hospital de la Santa Creu i Sant Pau","sponsor":"Palo Biofarma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PBF-2897","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hospital de la Santa Creu i Sant Pau","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de la Santa Creu i Sant Pau \/ Palo Biofarma","highestDevelopmentStatusID":"8","companyTruncated":"Hospital de la Santa Creu i Sant Pau \/ Palo Biofarma"},{"orgOrder":0,"company":"Hospital de la Santa Creu i Sant Pau","sponsor":"Palo Biofarma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"PBF-2897","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hospital de la Santa Creu i Sant Pau","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de la Santa Creu i Sant Pau \/ Palo Biofarma","highestDevelopmentStatusID":"8","companyTruncated":"Hospital de la Santa Creu i Sant Pau \/ Palo Biofarma"},{"orgOrder":0,"company":"Uppsala University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Uppsala University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Uppsala University \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"PT005","moa":"Adrenergic receptor beta-2 (ADRB2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PT005","moa":"Adrenergic receptor beta-2 (ADRB2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PT005","moa":"Adrenergic receptor beta-2 (ADRB2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BAY1097761","moa":"Adrenomedullin (ADM)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Population Services International","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Population Services International","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Population Services International"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"GSNOR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cavosonstat","moa":"Alcohol dehydrogenase class III","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSNOR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSNOR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSNOR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mirivadelgat","moa":"ALDH2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"QPS-Qualitix Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mirivadelgat","moa":"ALDH2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ QPS-Qualitix Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ QPS-Qualitix Clinical Research"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OncoArendi Therapeutics","amount2":0.38,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"OncoArendi Therapeutics \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"OncoArendi Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION-827359","moa":"Amiloride-sensitive sodium channel, ENaC mRNA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AV-001","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"AnGes","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ AnGes","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ AnGes"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"GSK2586881","moa":"Angiotensinogen","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GSK2586881","moa":"Angiotensinogen","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Melinta Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Imperial College London \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"antithrombotics (thromboxane A2 receptor antagonists)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"antithrombotics (thromboxane A2 receptor antagonists)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Zinpentraxin Alfa","moa":"APCS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Zinpentraxin Alfa","moa":"APCS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"PL-3994","moa":"Atrial natriuretic peptide receptor A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"KCRN Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ KCRN Research","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ KCRN Research"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BBT-877","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Biotech Acquisition Company"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Biotech Acquisition Company"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"University of Dundee","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Amino Acid","year":"2018","type":"Inapplicable","leadProduct":"Aztreonam Lysine","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Dundee","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"University of Dundee \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"University of Dundee \/ Gilead Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Abediterol","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Abediterol","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Abediterol","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Abediterol","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Abediterol","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abediterol","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Concentrx Pharmaceuticals","sponsor":"PharPoint Research | Kramer Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Concentrx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Concentrx Pharmaceuticals \/ PharPoint Research | Kramer Consulting","highestDevelopmentStatusID":"8","companyTruncated":"Concentrx Pharmaceuticals \/ PharPoint Research | Kramer Consulting"},{"orgOrder":0,"company":"Concentrx Pharmaceuticals","sponsor":"PharPoint Research | Kramer Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Concentrx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Concentrx Pharmaceuticals \/ PharPoint Research | Kramer Consulting","highestDevelopmentStatusID":"8","companyTruncated":"Concentrx Pharmaceuticals \/ PharPoint Research | Kramer Consulting"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acerus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AZD3199","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Indacaterol Maleate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Indacaterol Maleate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Levalbuterol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Olodaterol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Invion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Invion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Invion \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PT003","moa":"Beta-2 adrenergic receptor\/M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"PT003","moa":"Beta-2 adrenergic receptor\/M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PT003","moa":"Beta-2 adrenergic receptor\/M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Northside Hospital","sponsor":"Blood and Marrow Transplant Group of Georgia","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Northside Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northside Hospital \/ Blood and Marrow Transplant Group of Georgia","highestDevelopmentStatusID":"8","companyTruncated":"Northside Hospital \/ Blood and Marrow Transplant Group of Georgia"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"GW642444","moa":"bronchodilators (phenethylamine derivatives)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"GW642444","moa":"bronchodilators (phenethylamine derivatives)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"QAB149","moa":"bronchodilators (phenethylamine derivatives)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BLD-2660","moa":"Calpain","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD2423","moa":"C-C chemokine receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD2423","moa":"C-C chemokine receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ChemomAb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Undisclosed"},{"orgOrder":0,"company":"Axikin Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AXP1275","moa":"CCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axikin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Axikin Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axikin Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syntara Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"ASM8","moa":"CCR3 messenger RNA (CCR3 mRNA)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syntara Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntara Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syntara Limited \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tanzisertib","moa":"c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 3 | c-Jun N-terminal kinase 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"68-Ga CBP8","moa":"Collagen hydrolysis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"DevPro Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AP01","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avalyn Pharma \/ DevPro Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ DevPro Biopharma"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AP01","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avalyn Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Molgramostim","moa":"colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF)|colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RLS-0071","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"FG-3019","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Celgene Corporation"},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"DevPro Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Solrikitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uniquity Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniquity Bio \/ DevPro Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Uniquity Bio \/ DevPro Biopharma"},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Solrikitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uniquity Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniquity Bio \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Uniquity Bio \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"Solrikitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uniquity Bio","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Uniquity Bio \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Uniquity Bio \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Verekitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Undisclosed"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Verekitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Undisclosed"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series B Financing","leadProduct":"Verekitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Enavate Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Enavate Sciences"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Verekitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.26000000000000001,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ J.P. Morgan"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Verekitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Undisclosed"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Verekitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Upstream Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Undisclosed"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Verekitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Upstream Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SHR-1906","moa":"CTGF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SHR-1906","moa":"CTGF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Quintiles Inc"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"C-C chemokine receptor type 4 (CCR4)||CXCR-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scripps Health","sponsor":"University of California, San Diego | Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Health \/ University of California, San Diego | Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Scripps Health \/ University of California, San Diego | Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"University of Alabama at Birmingham | National Jewish Health | Temple University | University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ University of Alabama at Birmingham | National Jewish Health | Temple University | University of California, Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska \/ University of Alabama at Birmingham | National Jewish Health | Temple University | University of California, Los Angeles"},{"orgOrder":0,"company":"Global United Pharmaceutical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Phenazon","moa":"Cyclooxygenase-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Global United Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global United Pharmaceutical Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Global United Pharmaceutical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"National Heart, Lung, and Blood Institute | Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Alabama at Birmingham \/ National Heart, Lung, and Blood Institute | Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ National Heart, Lung, and Blood Institute | Vertex Pharmaceuticals"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Alabama at Birmingham \/ National Institute of Diabetes and Digestive and Kidney Diseases | Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ National Institute of Diabetes and Digestive and Kidney Diseases | Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"QBW251","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"QBW251","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"QBW251","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"QBW251","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Innovative Medicines Initiative"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Alberta Boehringer Ingelheim Collaboration","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Alberta Boehringer Ingelheim Collaboration","highestDevelopmentStatusID":"8","companyTruncated":"University of Alberta \/ Alberta Boehringer Ingelheim Collaboration"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Undisclosed"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HSK31858","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HSK31858","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Expedition Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"XH-S004","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fosun Pharmaceutical","amount2":0.65000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.65000000000000002,"dosageForm":"Tablet","sponsorNew":"Fosun Pharmaceutical \/ Expedition Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Fosun Pharmaceutical \/ Expedition Therapeutics"},{"orgOrder":0,"company":"Knopp Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Knopp Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Undisclosed"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Undisclosed"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Undisclosed"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Undisclosed"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Undisclosed"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Undisclosed"},{"orgOrder":0,"company":"Areteia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"DRD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Areteia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Areteia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Areteia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"Akebia Therapeutics | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at Houston \/ Akebia Therapeutics | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas Health Science Center at Houston \/ Akebia Therapeutics | US Department of Defense"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"BAY85-8501","moa":"ELA2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Boston University","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boston University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boston University \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Boston University \/ Johnson & Johnson"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Techpool Bio-Pharma","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Techpool Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Techpool Bio-Pharma \/ The First Affiliated Hospital of Guangzhou Medical University","highestDevelopmentStatusID":"8","companyTruncated":"Techpool Bio-Pharma \/ The First Affiliated Hospital of Guangzhou Medical University"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Desidustat","moa":"enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ FGK Clinical Research"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ FGK Clinical Research"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Flerie Invest","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Flerie Invest","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Flerie Invest"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanetics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ National Institutes of Health"},{"orgOrder":0,"company":"Pharmaceutics International","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmaceutics International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaceutics International \/ Humanetics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmaceutics International \/ Humanetics"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Cytokinetics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Cytokinetics","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Cytokinetics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pulmagen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ADC3680","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pulmagen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pulmagen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pulmagen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pulmagen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ADC3680B","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pulmagen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pulmagen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pulmagen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ARRY-502","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD1981","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD1981","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD1981","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BI671800","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BI671800","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BI671800","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BI671800","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fevipiprant","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"MK-1029","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"MK-1029","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"MK-1029","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"MK-1029","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"MK-1029","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Oxagen","sponsor":"Medicines Evaluation Unit, Manchester, UK | King's College Hospital NHS Trust","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"OC000459","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oxagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oxagen \/ Medicines Evaluation Unit, Manchester, UK | King's College Hospital NHS Trust","highestDevelopmentStatusID":"8","companyTruncated":"Oxagen \/ Medicines Evaluation Unit, Manchester, UK | King's College Hospital NHS Trust"},{"orgOrder":0,"company":"Oxagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"OC000459","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oxagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oxagen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxagen \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Atopix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"OC000459","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chiesi Group \/ Atopix Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Atopix Therapeutics"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Medical Research Council | Atopix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"OC459","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Medical Research Council | Atopix Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Imperial College London \/ Medical Research Council | Atopix Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"QAV680","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Setipiprant","moa":"G protein-coupled receptor 44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"PAION UK LTD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nantes University Hospital \/ PAION UK LTD","highestDevelopmentStatusID":"8","companyTruncated":"Nantes University Hospital \/ PAION UK LTD"},{"orgOrder":0,"company":"Galecto","sponsor":"Syneos Health | Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Syneos Health | Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Syneos Health | Biorasi"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.10000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Soleus Capital"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD5423","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AZD5423","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AZD5423","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"AZD7594","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZD7594","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZD7594","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AZD7594","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AZD7594","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AZD7594","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Hull University Teaching Hospitals NHS Trust","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hull University Teaching Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hull University Teaching Hospitals NHS Trust \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Hull University Teaching Hospitals NHS Trust \/ Chiesi Group"},{"orgOrder":0,"company":"University Hospital Antwerp","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University Hospital Antwerp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"University Hospital Antwerp \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Antwerp \/ Chiesi Group"},{"orgOrder":0,"company":"Activaero","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Activaero","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Activaero \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Activaero \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Corticosteroid","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University of British Columbia \/ AstraZeneca"},{"orgOrder":0,"company":"Dey","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dey","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dey \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dey \/ Undisclosed"},{"orgOrder":0,"company":"Dey","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dey","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dey \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dey \/ Undisclosed"},{"orgOrder":0,"company":"Dey","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dey","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dey \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dey \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"Novartis Pharmaceuticals Corporation | Crolll","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Novartis Pharmaceuticals Corporation | Crolll","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Novartis Pharmaceuticals Corporation | Crolll"},{"orgOrder":0,"company":"Vernalis","sponsor":"Manchester University NHS FT","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Indantadol","moa":"Glutamate [NMDA] receptor | Monoamine oxidase A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vernalis \/ Manchester University NHS FT","highestDevelopmentStatusID":"8","companyTruncated":"Vernalis \/ Manchester University NHS FT"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CX1739","moa":"Glutamate receptor ionotropic AMPA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ Duke University","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Duke University"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"GLPG1205","moa":"G-protein coupled receptor 84","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLPG1205","moa":"G-protein coupled receptor 84","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLPG1205","moa":"G-protein coupled receptor 84","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fezagepras","moa":"G-protein coupled receptor 84 | Free fatty acid receptor 1||GPR84","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Liminal BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Liminal BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fezagepras","moa":"G-protein coupled receptor 84 | Free fatty acid receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liminal BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Liminal BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GREECE","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Asklepion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asklepion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"National Jewish Health | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"University of Colorado, Denver \/ National Jewish Health | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ National Jewish Health | US Department of Defense"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gimsilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gimsilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gimsilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kinevant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kinevant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Kinevant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Kinevant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Kinevant Sciences"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinevant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"Virginia Commonwealth University | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ Virginia Commonwealth University | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ Virginia Commonwealth University | Sanofi"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ENV-101","moa":"Hedgehog signaling pathway (HS pathway)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Global Blood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Global Blood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD3427","moa":"HIF-2-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-38518168","moa":"Histamine H4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NITTO DENKO CORP","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ND-L02-s0201","moa":"HSP47","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"NITTO DENKO CORP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NITTO DENKO CORP \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NITTO DENKO CORP \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Heart, Lung, and Blood Institute | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ganciclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Heart, Lung, and Blood Institute | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ National Heart, Lung, and Blood Institute | Genentech"},{"orgOrder":0,"company":"Texas Tech University Health Sciences Center","sponsor":"Ainos","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Texas Tech University Health Sciences Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Texas Tech University Health Sciences Center \/ Ainos","highestDevelopmentStatusID":"8","companyTruncated":"Texas Tech University Health Sciences Center \/ Ainos"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MEMP1972A","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"MEMP1972A","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Novartis Pharmaceuticals Corporation | Hvidovre University Hospital | Herlev Hospital | Zealand University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rigshospitalet \/ Novartis Pharmaceuticals Corporation | Hvidovre University Hospital | Herlev Hospital | Zealand University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ Novartis Pharmaceuticals Corporation | Hvidovre University Hospital | Herlev Hospital | Zealand University Hospital"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"National Institute of Allergy and Infectious Diseases | Genentech | American Lung Association Asthma Clinical Research Centers | American Lung Association","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ National Institute of Allergy and Infectious Diseases | Genentech | American Lung Association Asthma Clinical Research Centers | American Lung Association","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ National Institute of Allergy and Infectious Diseases | Genentech | American Lung Association Asthma Clinical Research Centers | American Lung Association"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"JYB1904","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Rapt Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"JYB1904","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jemincare","amount2":0.70999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.70999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Rapt Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Rapt Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Oak Hill Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"OHB-607","moa":"IGF-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Oak Hill Bio","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Oak Hill Bio"},{"orgOrder":0,"company":"OHB Neonatology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"OHB-607","moa":"IGF-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OHB Neonatology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OHB Neonatology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OHB Neonatology \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Lunsekimig","moa":"IL13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lunsekimig","moa":"IL13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lunsekimig","moa":"IL13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CMK389","moa":"IL-18 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"MEDI8968","moa":"IL-1R1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Astegolimab","moa":"IL-33 receptor (ST2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"University of Leicester","sponsor":"Glenfield Hospital, Leicester | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MSTT1041A","moa":"IL-33 receptor (ST2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Leicester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"University of Leicester \/ Glenfield Hospital, Leicester | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Leicester \/ Glenfield Hospital, Leicester | Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"MSTT1041A","moa":"IL-33 receptor (ST2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Elarekibep","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Elarekibep","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"PureTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"hVIVO","sponsor":"Prep Biopharm Limited","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PrEP-001","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"hVIVO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"hVIVO \/ Prep Biopharm Limited","highestDevelopmentStatusID":"8","companyTruncated":"hVIVO \/ Prep Biopharm Limited"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Inner-City Asthma Consortium | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"German Cockroach Allergenic Extract","moa":"Immune system","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Inner-City Asthma Consortium | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Inner-City Asthma Consortium | Rho, Inc"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Mecasermin Rinfabate","moa":"Insulin-like growth factor I receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill Bio \/ Chiesi Group"},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Mecasermin Rinfabate","moa":"Insulin-like growth factor I receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill Bio \/ Chiesi Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Abituzumab","moa":"Integrin alpha-V\/beta-6 | Integrin alpha-V\/beta-5 | Integrin alpha-V\/beta-1 | Integrin alpha-V\/beta-8 | Integrin alpha-V\/beta-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Aerogen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Aerogen"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Parexel Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ Synairgen"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CJM112","moa":"Interleukin 17A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yale University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Eli Lilly"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Syntara Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2010","type":"Inapplicable","leadProduct":"TPI ASM8","moa":"Interleukin 3 receptor (CSF2RB)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syntara Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Syntara Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syntara Limited \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZD1402","moa":"Interleukin 4 receptor alpha (IL4R)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AZD1402","moa":"Interleukin 4 receptor alpha (IL4R)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CBP-201","moa":"Interleukin 4 receptor alpha (IL4R)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"PF-07275315","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"QAX576","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"QAX576","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"SAR156597","moa":"Interleukin-13 | Interleukin-4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"SAR156597","moa":"Interleukin-13 | Interleukin-4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kyowa Kirin | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Kyowa Kirin | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Kyowa Kirin | AstraZeneca"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Camoteskimab","moa":"Interleukin-18","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | PROMETHEUS LABS"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Etokimab","moa":"Interleukin-33","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Itepekimab","moa":"Interleukin-33","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"SAR440340","moa":"Interleukin-33","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"SAR440340","moa":"Interleukin-33","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"National Institute of Allergy and Infectious Diseases | Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ National Institute of Allergy and Infectious Diseases | Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas Health Science Center at San Antonio \/ National Institute of Allergy and Infectious Diseases | Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Childhood Asthma in Urban Settings | Regeneron Pharmaceuticals | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Childhood Asthma in Urban Settings | Regeneron Pharmaceuticals | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Childhood Asthma in Urban Settings | Regeneron Pharmaceuticals | Rho, Inc"},{"orgOrder":0,"company":"Temple University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ GSK"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Inner-City Asthma Consortium | GSK | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Inner-City Asthma Consortium | GSK | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Inner-City Asthma Consortium | GSK | Rho, Inc"},{"orgOrder":0,"company":"Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Reslizumab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Reslizumab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"Temple University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Temple University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ AstraZeneca"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Jewish Health \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ AstraZeneca"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reparixin","moa":"Interleukin-8 receptor A | Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Danirixin","moa":"Interleukin-8 receptor B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Integrin alpha-5\/beta-1 (ITGA5\/B1)||ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Stanford University","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Stanford University"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Integrin alpha-5\/beta-1 (ITGA5\/B1)||ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Integrin alpha-5\/beta-1 (ITGA5\/B1)||ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Integrin alpha-5\/beta-1 (ITGA5\/B1)||ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Integrin alpha-5\/beta-1 (ITGA5\/B1)||ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Citigroup","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Citigroup"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series C Financing","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Oxford Finance","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Oxford Finance"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"ITGB6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AZD4604","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AZD4604","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AZD4604","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AZD4604","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Quotient Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Quotient Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AZD4604","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TD-8236","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TD-8236","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"R348","moa":"Janus kinase 3 (JAK-3)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"CC-90001","moa":"JNK kinase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"RCSI University of Medicine and Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1-antitrypsin","moa":"Leukocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RCSI University of Medicine and Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RCSI University of Medicine and Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RCSI University of Medicine and Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Leukocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BIIL 284 BS","moa":"Leukotriene B4 receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BIIL 284 BS","moa":"Leukotriene B4 receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BIIL 284 BS","moa":"Leukotriene B4 receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"ES Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"AVTX-007","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ ES Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ ES Therapeutics"},{"orgOrder":0,"company":"Polyphor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Murepavadin","moa":"LPS-assembly protein LptD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polyphor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polyphor \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"JNJ-40929837","moa":"LTA4H","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HZN-825","moa":"LyLPAR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"BMS-986020","moa":"Lysophosphatidic acid receptor Edg-2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Simtuzumab","moa":"Lysyl oxidase homolog 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Simtuzumab","moa":"Lysyl oxidase homolog 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Simtuzumab","moa":"Lysyl oxidase homolog 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Miami \/ Incyte Corporation"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"DevPro Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ DevPro Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ DevPro Biopharma"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMB-05X","moa":"Macrophage colony-stimulating factor 1 receptor (CSF1R)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AmMax Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PF-03715455","moa":"MAP kinase p38 alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"PF-03715455","moa":"MAP kinase p38 alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PF-03715455","moa":"MAP kinase p38 alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PH-797804","moa":"MAP kinase p38 alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PH-797804","moa":"MAP kinase p38 alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Technology Strategy Board, United Kingdom | GSK | Royal Brompton & Harefield NHS FT | University of Cambridge","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAP kinase p38 alpha | MAP kinase p38 beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Technology Strategy Board, United Kingdom | GSK | Royal Brompton & Harefield NHS FT | University of Cambridge","highestDevelopmentStatusID":"8","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Technology Strategy Board, United Kingdom | GSK | Royal Brompton & Harefield NHS FT | University of Cambridge"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAP kinase p38 alpha | MAP kinase p38 beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAP kinase p38 alpha | MAP kinase p38 beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Respivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Cromoglicate","moa":"MasT-cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Respivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"FP-025","moa":"Matrix metalloproteinase-12 (MMP-12)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Repository Corticotropin","moa":"Melanocortin receptor 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Thirty Respiratory Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RESP301","moa":"Membrane fusion protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Thirty Respiratory Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thirty Respiratory Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Thirty Respiratory Limited \/ Undisclosed"},{"orgOrder":0,"company":"EmeraMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Emeramide","moa":"Mercury | Iron","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EmeraMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmeraMed \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Linvemastat","moa":"MMP-12","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"GSK3772847","moa":"monoclonal antibodies: immunomodulating","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"GSK3772847","moa":"monoclonal antibodies: immunomodulating","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MEDI3506","moa":"monoclonal antibodies: interleukins","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tozorakimab","moa":"monoclonal antibodies: interleukins","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ University of Washington"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mitiperstat","moa":"MPO","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Aer Therapeutics","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"Fexlamose","moa":"Mucin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aer Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.040000000000000001,"dosageForm":"Inhalation","sponsorNew":"Aer Therapeutics \/ Canaan Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aer Therapeutics \/ Canaan Partners"},{"orgOrder":0,"company":"Aer Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fexlamose","moa":"Mucin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aer Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aer Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Renovion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Renovion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Renovion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Renovion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Renovion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"EP-101","moa":"Muscarinic acetylcholine receptor (CHRM)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"EP-101","moa":"Muscarinic acetylcholine receptor (CHRM)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Quintiles Inc"},{"orgOrder":0,"company":"Niox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Niox","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Niox \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Niox \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Batefenterol","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Batefenterol","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Batefenterol","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Batefenterol","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Batefenterol","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD8683","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AZD8683","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AZD8683","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Theravance Biopharma | Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"University of California, Los Angeles \/ Theravance Biopharma | Viatris","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ Theravance Biopharma | Viatris"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Nephron Pharmaceuticals Corporation","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nephron Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nephron Pharmaceuticals Corporation \/ Rho Inc","highestDevelopmentStatusID":"8","companyTruncated":"Nephron Pharmaceuticals Corporation \/ Rho Inc"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Umeclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Theron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"TRN-157","moa":"Muscarinic acetylcholine receptor M3 (CHRM3)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AZD8871","moa":"Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AZD8871","moa":"Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AZD8871","moa":"Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel | Almirall | The Doctors Laboratory Ltd | Covance","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AZD8871","moa":"Muscarinic acetylcholine receptor M3 | Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AstraZeneca \/ Parexel | Almirall | The Doctors Laboratory Ltd | Covance","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel | Almirall | The Doctors Laboratory Ltd | Covance"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University of Miami \/ AstraZeneca"},{"orgOrder":0,"company":"Asmacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ASM-024","moa":"Muscarinic acetylcholine receptor M3 | Neuronal acetylcholine receptor protein alpha-7 subunit | Neuronal acetylcholine receptor; alpha3\/beta4 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Asmacure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Asmacure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asmacure \/ Undisclosed"},{"orgOrder":0,"company":"Asmacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ASM-024","moa":"Muscarinic acetylcholine receptor M3 | Neuronal acetylcholine receptor protein alpha-7 subunit | Neuronal acetylcholine receptor; alpha3\/beta4 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Asmacure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Asmacure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asmacure \/ Undisclosed"},{"orgOrder":0,"company":"Asmacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ASM-024","moa":"Muscarinic acetylcholine receptor M3 | Neuronal acetylcholine receptor protein alpha-7 subunit | Neuronal acetylcholine receptor; alpha3\/beta4 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Asmacure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Asmacure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asmacure \/ Undisclosed"},{"orgOrder":0,"company":"Asmacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ASM-024","moa":"Muscarinic acetylcholine receptor M3 | Neuronal acetylcholine receptor protein alpha-7 subunit | Neuronal acetylcholine receptor; alpha3\/beta4 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Asmacure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Asmacure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asmacure \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"QVM149","moa":"Muscarinic receptor\/Long-acting beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"QVM149","moa":"Muscarinic receptor\/Long-acting beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BIO-11006","moa":"Myristoylated alanine-rich C-kinase substrate","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Biomarck Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BIO-11006","moa":"Myristoylated alanine-rich C-kinase substrate","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acquist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Acquist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acquist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BIO-11006","moa":"Myristoylated alanine-rich C-kinase substrate","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Biomarck Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NTX-1175","moa":"Na channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nocion Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Attenua","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bradanicline","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Attenua","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attenua \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attenua \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TC-6987","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Promedior","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"PRM-151","moa":"Neuronal pentraxin-2 (NPTX2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Promedior","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Promedior \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Promedior \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"QATAR","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"Canadian Institutes of Health Research | Alberta Children's Hospital | CHU Sainte-Justine | Children's Hospital of Eastern Ontario | Stollery Children's Hospital | The Children's Hospital of Winnipeg | Provincial Health Services Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Hospital for Sick Children \/ Canadian Institutes of Health Research | Alberta Children's Hospital | CHU Sainte-Justine | Children's Hospital of Eastern Ontario | Stollery Children's Hospital | The Children's Hospital of Winnipeg | Provincial Health Services Authority","highestDevelopmentStatusID":"8","companyTruncated":"The Hospital for Sick Children \/ Canadian Institutes of Health Research | Alberta Children's Hospital | CHU Sainte-Justine | Children's Hospital of Eastern Ontario | Stollery Children's Hospital | The Children's Hospital of Winnipeg | Provincial Health Services Authority"},{"orgOrder":0,"company":"University College London","sponsor":"Cure Parkinson\u2019S Trust","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Ambroxol","moa":"NO dependent soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College London \/ Cure Parkinson\u2019S Trust","highestDevelopmentStatusID":"8","companyTruncated":"University College London \/ Cure Parkinson\u2019S Trust"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.050000000000000003,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Parexel"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu|kappa|delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FB704A","moa":"OX40","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eliapixant","moa":"P2RX3||P2X3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sivopixant","moa":"P2RX3||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"BELLUS Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Camlipixant","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"adMare BioInnovations \/ BELLUS Health","highestDevelopmentStatusID":"8","companyTruncated":"adMare BioInnovations \/ BELLUS Health"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BELLUS Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Createrna Science and Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"QR052107B","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Createrna Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Createrna Science and Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Createrna Science and Technology \/ Undisclosed"},{"orgOrder":0,"company":"Createrna Science and Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"QR052107B","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Createrna Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Createrna Science and Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Createrna Science and Technology \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Uridine Triphosphate","moa":"P2Y2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Acumapimod","moa":"p38 MAPK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mereo BioPharma Group \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Acumapimod","moa":"p38 MAPK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"CervoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CervoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Cancer Hospital","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sichuan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Cancer Hospital \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Cancer Hospital \/ Innovent Biologics"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HSK44459","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HSK44459","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Apeptico","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRIA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"AP301","moa":"peptides","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Apeptico","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Apeptico \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeptico \/ Undisclosed"},{"orgOrder":0,"company":"Apeptico","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRIA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Solnatide","moa":"peptides","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Apeptico","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Apeptico \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeptico \/ Undisclosed"},{"orgOrder":0,"company":"Aquinox Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"AQX-1125","moa":"Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aquinox Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aquinox Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquinox Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Revamilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Glenmark Pharmaceuticals \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Laval University","sponsor":"Innovair | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Innovair | Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Laval University \/ Innovair | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tanimilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tanimilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tanimilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Duke University | Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Duke University | Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Duke University | Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"University Teaching Hospital, Lusaka, Zambia | Egerton University | Cameroon Baptist Convention Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Alabama at Birmingham \/ University Teaching Hospital, Lusaka, Zambia | Egerton University | Cameroon Baptist Convention Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ University Teaching Hospital, Lusaka, Zambia | Egerton University | Cameroon Baptist Convention Health"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"VA Boston Healthcare System | Atlanta VA Medical Center | VA Eastern Colorado Health Care System | VA Nebraska Western Iowa Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VA Office of Research and Development \/ VA Boston Healthcare System | Atlanta VA Medical Center | VA Eastern Colorado Health Care System | VA Nebraska Western Iowa Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ VA Boston Healthcare System | Atlanta VA Medical Center | VA Eastern Colorado Health Care System | VA Nebraska Western Iowa Health Care System"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ BARDA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZD8154","moa":"PI3-kinase delta (PIK3CD)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AZD8154","moa":"PI3-kinase delta (PIK3CD)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZD8154","moa":"PI3-kinase delta (PIK3CD)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Calluna Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Calluna Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Calluna Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Calluna Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Calluna Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Calluna Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Calluna Pharma \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Calluna Pharma \/ Forbion"},{"orgOrder":0,"company":"Calluna Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Calluna Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calluna Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Calluna Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"SecuraBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SecuraBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SecuraBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SecuraBio \/ Undisclosed"},{"orgOrder":0,"company":"Acticor Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"Platelet glycoprotein VI (GPVI)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acticor Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acticor Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Holdsworth House Medical Practice","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Holdsworth House Medical Practice","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holdsworth House Medical Practice \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Holdsworth House Medical Practice \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Temple University","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Temple University \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor | Fibroblast growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor | Fibroblast growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avalyn Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor | Fibroblast growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avalyn Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enalare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enalare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enalare Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Enalare Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Bioclinica","sponsor":"Direct Biologics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Partnership","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bioclinica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioclinica \/ Direct Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Bioclinica \/ Direct Biologics"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"F4 Pharma","sponsor":"Assistance Publique Hopitaux de Paris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRIA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FX06","moa":"Pro-inflammatory fibrin E1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F4 Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F4 Pharma \/ Assistance Publique Hopitaux de Paris","highestDevelopmentStatusID":"8","companyTruncated":"F4 Pharma \/ Assistance Publique Hopitaux de Paris"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"GB001","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ BofA Securities"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"University of North Carolina \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ United Therapeutics"},{"orgOrder":0,"company":"Aerogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Epoprostenol Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aerogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"University of S\u00e3o Paulo General Hospital","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of S\u00e3o Paulo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of S\u00e3o Paulo General Hospital \/ Janssen-Cilag","highestDevelopmentStatusID":"8","companyTruncated":"University of S\u00e3o Paulo General Hospital \/ Janssen-Cilag"},{"orgOrder":0,"company":"University of Florida","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ United Therapeutics"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inova Health Care Services \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tetherex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SelK2","moa":"P-selectin glycoprotein ligand 1 (SELPLG)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tetherex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetherex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tetherex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Aerogen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"AP-002","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists||RANKL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nuance Pharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20999999999999999,"dosageForm":"Inhalation","sponsorNew":"Nuance Pharma \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Nuance Pharma \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AP-002","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Undisclosed"},{"orgOrder":0,"company":"Deerfield Management","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Termination","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Deerfield Management","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Deerfield Management \/ Windtree Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Deerfield Management \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"L-Alfa-Glu-Afc","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Newcastle NHS Trust","sponsor":"AstraZeneca | Newcastle University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Newcastle NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Newcastle NHS Trust \/ AstraZeneca | Newcastle University","highestDevelopmentStatusID":"8","companyTruncated":"Newcastle NHS Trust \/ AstraZeneca | Newcastle University"},{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"SynaVir","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers, The State University of New Jersey \/ SynaVir","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers, The State University of New Jersey \/ SynaVir"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"GSK573719","moa":"quaternary ammonium derivatives: muscarinic receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"GSK573719","moa":"quaternary ammonium derivatives: muscarinic receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ADX-629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ADX-629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Mtec","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Mtec","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Mtec"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AZD6793","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Afimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DS102","moa":"Reperfusion stress","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Afimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Altium Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Altium Capital","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Altium Capital"},{"orgOrder":0,"company":"GRI Bio","sponsor":"NIHR Respiratory TRC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ NIHR Respiratory TRC","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ NIHR Respiratory TRC"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GRI Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Northside Hospital","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Northside Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northside Hospital \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Northside Hospital \/ Sanofi"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Sanofi | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Sanofi | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Sanofi | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Sanofi"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Simbec-Orion","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Simbec-Orion","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Simbec-Orion"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TDI01","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Beijing Tide Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tide Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Graviton","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"TDI01","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.52000000000000002,"dosageForm":"Suspension","sponsorNew":"Beijing Tide Pharmaceutical \/ Graviton","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tide Pharmaceutical \/ Graviton"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Rho, Inc"},{"orgOrder":0,"company":"Ethris","sponsor":"EU4Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Funding","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ EU4Health","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ EU4Health"},{"orgOrder":0,"company":"Ethris","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ethris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Undisclosed"},{"orgOrder":0,"company":"Ethris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Undisclosed"},{"orgOrder":0,"company":"Ethris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Undisclosed"},{"orgOrder":0,"company":"Ethris","sponsor":"VirTus Respiratory Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethris \/ VirTus Respiratory Research Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ VirTus Respiratory Research Ltd"},{"orgOrder":0,"company":"Revotar Biopharmaceuticals AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bimosiamose","moa":"Selectin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Revotar Biopharmaceuticals AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revotar Biopharmaceuticals AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revotar Biopharmaceuticals AG \/ Undisclosed"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"LAM-001","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"OrphAI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-lipoxygenase activating protein||Serotonin 1a (5-HT1a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-lipoxygenase activating protein||Serotonin 1a (5-HT1a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-lipoxygenase activating protein||Serotonin 1a (5-HT1a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-lipoxygenase activating protein||Serotonin 1a (5-HT1a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-lipoxygenase activating protein||Serotonin 1a (5-HT1a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-lipoxygenase activating protein||Serotonin 1a (5-HT1a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"HumanKindLabs | University of Copenhagen | CTC Clinical Trial Consultants | OPEN Foundation | IESE Business School | Uppsala University | Champalimaud Centre | Stockholm University | University of Groningen | National Institute of Mental Health, Prague | ","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ HumanKindLabs | University of Copenhagen | CTC Clinical Trial Consultants | OPEN Foundation | IESE Business School | Uppsala University | Champalimaud Centre | Stockholm University | University of Groningen | National Institute of Mental Health, Prague | ","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ HumanKindLabs | University of Copenhagen | CTC Clinical Trial Consultants | OPEN Foundation | IESE Business School | Uppsala University | Champalimaud Centre | Stockholm University | University of Groningen | National Institute of Mental Health, Prague | "},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tenax Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tenax Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pulmovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mosliciguat","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pulmovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pulmovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pulmovant \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Ally Bridge Group","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Ally Bridge Group"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Omega Funds"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ AyurMaya"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Taladegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"GSK","sponsor":"North West Lung Centre","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK2339345","moa":"Sodium channel unspecific (NaC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ North West Lung Centre","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ North West Lung Centre"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GSK2339345","moa":"Sodium channel unspecific (NaC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GSK2339345","moa":"Sodium channel unspecific (NaC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Duke University | Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Duke University | Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Duke University | Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Bellerophon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Bellerophon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Rabin Medical Center \/ Bellerophon Therapeutics"},{"orgOrder":0,"company":"Bellerophon Pulse Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bellerophon Pulse Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellerophon Pulse Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bellerophon Pulse Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bellerophon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bellerophon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Hospital Organization Okayama Medical Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Hospital Organization Okayama Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Hospital Organization Okayama Medical Center \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"National Hospital Organization Okayama Medical Center \/ Bayer AG"},{"orgOrder":0,"company":"Heidelberg University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Heidelberg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Heidelberg University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Heidelberg University \/ Merck & Co"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Frespaciguat","moa":"Soluble guanylate cyclase (sGC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ponesimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"TTI-101","moa":"STAT3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Tvardi Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"TTI-101","moa":"STAT3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Tvardi Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Tvardi Therapeutics"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Exvastat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Exvastat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Exvastat \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Exvastat \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Jurjan Aman","sponsor":"Simbec-Orion | Exvastat | KABS laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dr. Jurjan Aman","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Jurjan Aman \/ Simbec-Orion | Exvastat | KABS laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Jurjan Aman \/ Simbec-Orion | Exvastat | KABS laboratories"},{"orgOrder":0,"company":"Neurophyxia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"2-iminobiotin","moa":"Streptavidin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Neurophyxia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurophyxia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurophyxia \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"AZD7624","moa":"Stress-activated protein kinase (p38)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AZD7624","moa":"Stress-activated protein kinase (p38)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AZD7624","moa":"Stress-activated protein kinase (p38)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"AZD7624","moa":"Stress-activated protein kinase (p38)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"18-F FSPG","moa":"System xC- transporter","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Stanford University \/ GE Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ GE Healthcare"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Opelconazole","moa":"systemic antifungals (miconazole type)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Pulmocide \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Undisclosed"},{"orgOrder":0,"company":"Melius Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suplatast Tosilate","moa":"T(H2) cytokine production (TH2 produ)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Melius Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Melius Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Melius Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Orvepitant Maleate","moa":"TACR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"NeRRe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeRRe Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeRRe Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Pharm-Olam","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orvepitant Maleate","moa":"TACR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"NeRRe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeRRe Therapeutics \/ Pharm-Olam","highestDevelopmentStatusID":"8","companyTruncated":"NeRRe Therapeutics \/ Pharm-Olam"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Orvepitant Maleate","moa":"TACR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"NeRRe Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"NeRRe Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"NeRRe Therapeutics \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Qureight","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Qureight","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Qureight"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Alefacept","moa":"T-cell surface antigen CD2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Astellas Pharma"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BG00011","moa":"TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BG00011","moa":"TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medsenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medsenic \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Terbogrel","moa":"Thromboxane A2 receptor | Thromboxane-A synthase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Terbogrel","moa":"Thromboxane A2 receptor | Thromboxane-A synthase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MEDI9929","moa":"Thymic stromal lymphopoietin (TSLP)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"MEDI9929","moa":"Thymic stromal lymphopoietin (TSLP)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"Uni-Pharma SA","sponsor":"Attikon Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GREECE","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uni-Pharma SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uni-Pharma SA \/ Attikon Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Uni-Pharma SA \/ Attikon Hospital"},{"orgOrder":0,"company":"Denver Health and Hospital Authority","sponsor":"Genentech | University of Colorado, Denver | National Jewish Health | Beth Israel Deaconess Medical Center | Long Island Jewish Medical Center | Scripps Health | St. Mary's Medical Center | University of Miami | Ben Taub Hospital | The Methodist Hospital ","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Denver Health and Hospital Authority","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Denver Health and Hospital Authority \/ Genentech | University of Colorado, Denver | National Jewish Health | Beth Israel Deaconess Medical Center | Long Island Jewish Medical Center | Scripps Health | St. Mary's Medical Center | University of Miami | Ben Taub Hospital | The Methodist Hospital ","highestDevelopmentStatusID":"8","companyTruncated":"Denver Health and Hospital Authority \/ Genentech | University of Colorado, Denver | National Jewish Health | Beth Israel Deaconess Medical Center | Long Island Jewish Medical Center | Scripps Health | St. Mary's Medical Center | University of Miami | Ben Taub Hospital | The Methodist Hospital "},{"orgOrder":0,"company":"University of Michigan","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Michigan \/ Genentech"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South West Sydney Local Health District \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"South West Sydney Local Health District \/ Undisclosed"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Beijing Continent Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beijing Continent Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Continent Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Continent Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Kawin Technology Share-Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beijing Kawin Technology Share-Holding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Kawin Technology Share-Holding \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Kawin Technology Share-Holding \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pulmonary Hospital","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Pulmonary Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pulmonary Hospital \/ Nanjing Chia-tai Tianqing Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pulmonary Hospital \/ Nanjing Chia-tai Tianqing Pharmaceutical"},{"orgOrder":0,"company":"Fujian Medical University Union Hospital","sponsor":"Beijing Continent Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fujian Medical University Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Medical University Union Hospital \/ Beijing Continent Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Medical University Union Hospital \/ Beijing Continent Pharmaceutical"},{"orgOrder":0,"company":"Beijing Continent Pharmaceutical","sponsor":"Shanghai Genomics, Inc. | GNI Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beijing Continent Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Continent Pharmaceutical \/ Shanghai Genomics, Inc. | GNI Group","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Continent Pharmaceutical \/ Shanghai Genomics, Inc. | GNI Group"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, San Francisco \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Francisco \/ Genentech"},{"orgOrder":0,"company":"Pulmonary Research of Abingdon","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pulmonary Research of Abingdon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pulmonary Research of Abingdon \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Pulmonary Research of Abingdon \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Avalyn Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Avalyn Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"GSK2862277","moa":"TNFR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Value Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Series E Financing","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Value Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Value Partners Group"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"BHR Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Series D Financing","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ BHR Partners","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ BHR Partners"},{"orgOrder":0,"company":"GSK","sponsor":"PATH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"GSK2245035","moa":"Toll-like receptor 7","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ PATH","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ PATH"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"GSK2245035","moa":"Toll-like receptor 7","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK2245035","moa":"Toll-like receptor 7","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"GSK2245035","moa":"Toll-like receptor 7","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"AZD1419","moa":"Toll-like receptor 9 (TLR9)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Cytos Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"CYT003","moa":"Toll-like receptor 9 (TLR9)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cytos Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytos Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytos Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Cytos Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CYT003","moa":"Toll-like receptor 9 (TLR9)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cytos Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytos Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytos Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Pulmotect","sponsor":"Imperial College Healthcare NHS Trust | VirTus Respiratory Research Ltd | MWB Consulting Ltd | Data Magik","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"PUL-042","moa":"Toll-like-9 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pulmotect \/ Imperial College Healthcare NHS Trust | VirTus Respiratory Research Ltd | MWB Consulting Ltd | Data Magik","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect \/ Imperial College Healthcare NHS Trust | VirTus Respiratory Research Ltd | MWB Consulting Ltd | Data Magik"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"GSK2798745","moa":"Transient receptor potential cation channel subfamily V member 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"QBX258","moa":"Treg cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FINLAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"Troponin, cardiac muscle | Phosphodiesterase 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orion Corporation \/ Tenax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corporation \/ Tenax Therapeutics"},{"orgOrder":0,"company":"Axalbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Undisclosed"},{"orgOrder":0,"company":"Axalbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Undisclosed"},{"orgOrder":0,"company":"Axalbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Undisclosed"},{"orgOrder":0,"company":"Axalbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD8630","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AZD8630","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AZD8630","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD8630","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CM326","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MG-ZG122","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MG-ZG122","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Windward Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"WIN378","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windward Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Windward Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windward Bio \/ Undisclosed"},{"orgOrder":0,"company":"Xentria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Tumor necrosis factor (TNF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Undisclosed"},{"orgOrder":0,"company":"Xentria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Tumor necrosis factor (TNF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Undisclosed"},{"orgOrder":0,"company":"Xentria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Tumor necrosis factor (TNF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Undisclosed"},{"orgOrder":0,"company":"Xentria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Tumor necrosis factor (TNF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Undisclosed"},{"orgOrder":0,"company":"Xentria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Tumor necrosis factor (TNF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Undisclosed"},{"orgOrder":0,"company":"Xentria","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"XTMAB-16","moa":"Tumor necrosis factor (TNF)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Alabama at Birmingham \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ GSK"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AVTX-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Quisovalimab","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Apollo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Apollo Therapeutics"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Quisovalimab","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Scleroderma Research Foundation","sponsor":"Sanofi | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Scleroderma Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scleroderma Research Foundation \/ Sanofi | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Scleroderma Research Foundation \/ Sanofi | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Pfizer Inc"},{"orgOrder":0,"company":"Stanford University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stanford University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Eli Lilly"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Entospletinib","moa":"Tyrosine-protein kinase SYK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Rigel Pharmaceuticals | Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Rigel Pharmaceuticals | Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Inova Health Care Services \/ Rigel Pharmaceuticals | Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"R940343","moa":"Tyrosine-protein kinase SYK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sterna Biologicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SB010","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sterna Biologicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sterna Biologicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sterna Biologicals \/ Undisclosed"},{"orgOrder":0,"company":"Sterna Biologicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SB010","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sterna Biologicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sterna Biologicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sterna Biologicals \/ Undisclosed"},{"orgOrder":0,"company":"Sterna Biologicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SB010","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sterna Biologicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sterna Biologicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sterna Biologicals \/ Undisclosed"},{"orgOrder":0,"company":"Sterna Biologicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SB010","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sterna Biologicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sterna Biologicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sterna Biologicals \/ Undisclosed"},{"orgOrder":0,"company":"Throne Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mononuclear Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Throne Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Throne Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Throne Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Vitti Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VL-PX10","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vitti Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitti Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vitti Labs \/ Undisclosed"},{"orgOrder":0,"company":"Xemed","sponsor":"University of Virginia | National Institutes of Health | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Magnixene","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xemed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xemed \/ University of Virginia | National Institutes of Health | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Xemed \/ University of Virginia | National Institutes of Health | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"A006","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"A006","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"A006","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acebrophylline","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Advagene Biopharma","sponsor":"Taipei Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AD17002","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Advagene Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advagene Biopharma \/ Taipei Medical University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Advagene Biopharma \/ Taipei Medical University Hospital"},{"orgOrder":0,"company":"Istituto Auxologico Italiano","sponsor":"Apnimed | VIS Ethic Research Srl | University of Florence | STM Pharma PRO srl","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AD981","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Istituto Auxologico Italiano","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Istituto Auxologico Italiano \/ Apnimed | VIS Ethic Research Srl | University of Florence | STM Pharma PRO srl","highestDevelopmentStatusID":"8","companyTruncated":"Istituto Auxologico Italiano \/ Apnimed | VIS Ethic Research Srl | University of Florence | STM Pharma PRO srl"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3999999999999999,"dosageForm":"Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ GSK"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series A Financing","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Aiolos Bio \/ Atlas Venture","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3999999999999999,"dosageForm":"Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ GSK"},{"orgOrder":0,"company":"Shanghai Ark Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AK3280","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Ark Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Ark Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AK3280","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ark Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ark Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ark Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Korea Arlico Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ALC-2203-1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Korea Arlico Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea Arlico Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Korea Arlico Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"SarcoMed","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Alidornase Alpha","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SarcoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SarcoMed \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SarcoMed \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aqualung Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aqualung Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aqualung Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aqualung Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Funding","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aqualung Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Aqualung Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aqualung Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aqualung Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aqualung Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aqualung Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hull University Teaching Hospitals NHS Trust","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Ambroxol Hydrochloride","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hull University Teaching Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Hull University Teaching Hospitals NHS Trust \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hull University Teaching Hospitals NHS Trust \/ Sanofi"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva Strategic Opportunities LLC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Agreement","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities LLC"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Financing","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"AP\u2010PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Agreement","leadProduct":"AP\u2010PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"AP\u2010PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ARS-1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ontario Clinical Oncology Group","sponsor":"Aboca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Artichoke Extract","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ontario Clinical Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ontario Clinical Oncology Group \/ Aboca","highestDevelopmentStatusID":"8","companyTruncated":"Ontario Clinical Oncology Group \/ Aboca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD0292","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AZD2115","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"AZD2115","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AZD2115","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ba679BR","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BEA2180BR","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BI 765423","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BI1819479","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BI1839100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"PharmaKing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Broussonetia","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PharmaKing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaKing \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaKing \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CHF 1535","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CHF 5259","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CHF1531","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"CHF5188","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"CHF5633","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CHF5633","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CHF718","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CM512","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CM512","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CNTO 6785","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"RSPR Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CRD007","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RSPR Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RSPR Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RSPR Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RSPR Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CRD007","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RSPR Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RSPR Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RSPR Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CSL787","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CSL787","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"AIM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"D-Cyclohexylalanine-D-Glutamic-Glycine Tripeptide","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AIM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"AIM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AIM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Microbio Shanghai","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"FB825","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oneness Biotech \/ Microbio Shanghai","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Microbio Shanghai"},{"orgOrder":0,"company":"Aer Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Flexlamose","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Aer Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aer Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"FP 100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"FP01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"FP01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"National Institute for Health and Care Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rejuvenate Biomed \/ National Institute for Health and Care Research","highestDevelopmentStatusID":"8","companyTruncated":"Rejuvenate Biomed \/ National Institute for Health and Care Research"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GDC-6599","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"GEn1E Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GEn-1124","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GEn1E Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GEn1E Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GEn1E Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"GSK3277511A","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GSK3277511A","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GSK3277511A","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"GSK3277511A","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GSK3915393","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GSK3915393","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GSK5784283","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GW766944","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"GW870086","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"GW870086","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huilun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"H057","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Huilun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Huilun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Huilun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HEC585","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"HEX17","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen \/ Thairm Bio"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HL301","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRG2005","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-2261","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HRS-2261","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-9813","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HSK39004","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HSK39004","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiuzhitang Maker Cell Technology","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Bone Marrow Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiuzhitang Maker Cell Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiuzhitang Maker Cell Technology \/ The First Affiliated Hospital of Guangzhou Medical University","highestDevelopmentStatusID":"8","companyTruncated":"Jiuzhitang Maker Cell Technology \/ The First Affiliated Hospital of Guangzhou Medical University"},{"orgOrder":0,"company":"Duke University","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Hyperpolarized 129 Xenon Gas","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Duke University | Children's Hospital Medical Center, Cincinnati | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Hyperpolarized Xenon-129","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas Medical Center \/ Duke University | Children's Hospital Medical Center, Cincinnati | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"University of Kansas Medical Center \/ Duke University | Children's Hospital Medical Center, Cincinnati | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"CSL Behring | Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ CSL Behring | Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Ottawa Hospital Research Institute \/ CSL Behring | Grifols International"},{"orgOrder":0,"company":"Rochester General Hospital","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rochester General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rochester General Hospital \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Rochester General Hospital \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University Hospital Regensburg","sponsor":"ClinAssess","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Interferon Gamma 1B","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University Hospital Regensburg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Regensburg \/ ClinAssess","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Regensburg \/ ClinAssess"},{"orgOrder":0,"company":"PharmaLundensis AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"3-Iodo-2-propynyl butylcarbamate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PharmaLundensis AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PharmaLundensis AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaLundensis AB \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ISM001-055","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ISM001-055","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Engelhard Arzneimittel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Ivy Leaves","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Engelhard Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Engelhard Arzneimittel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Engelhard Arzneimittel \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ-39758979","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-49095397","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"KHK4563","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Modern Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Leramistat","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Modern Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modern Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Modern Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Rein Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"LTI-01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rein Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rein Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rein Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"LTI-01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lung Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lung Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Rein Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rein Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Rein Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rein Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rein Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rein Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Rein Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rein Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rein Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rein Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Rein Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rein Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LTP001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Mequitazine","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MTX-463","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MTX-463","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"MTX-463","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mediar Therapeutics","amount2":0.79000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.79000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Mediar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"PharmaKing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"N02RS1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PharmaKing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PharmaKing \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaKing \/ Undisclosed"},{"orgOrder":0,"company":"Attgeno","sponsor":"Aurevia","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitrosooxypropanol","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Attgeno","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attgeno \/ Aurevia","highestDevelopmentStatusID":"8","companyTruncated":"Attgeno \/ Aurevia"},{"orgOrder":0,"company":"Attgeno","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitrosooxypropanol","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Attgeno","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attgeno \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attgeno \/ Undisclosed"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NOC-110","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nocion Therapeutics \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ IQVIA"},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"DevPro Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NSI-8226","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uniquity Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniquity Bio \/ DevPro Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Uniquity Bio \/ DevPro Biopharma"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NTHi-10-AS01E","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ONO-6950","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ONO-6950","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Patara Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"PA101","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Patara Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Patara Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Patara Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PD 0360324","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PF-07868489","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"QAX028","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"QBM076","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"QMF149","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Brigham and Women's Hospital | Therabron Therapeutics, Inc. | Baystate Medical Center | Poznan University of Medical Sciences | University Hospital Krakow, Neonatology Unit | Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Recombinant human Clara cell 10kDa protein","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tufts Medical Center \/ Brigham and Women's Hospital | Therabron Therapeutics, Inc. | Baystate Medical Center | Poznan University of Medical Sciences | University Hospital Krakow, Neonatology Unit | Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii","highestDevelopmentStatusID":"8","companyTruncated":"Tufts Medical Center \/ Brigham and Women's Hospital | Therabron Therapeutics, Inc. | Baystate Medical Center | Poznan University of Medical Sciences | University Hospital Krakow, Neonatology Unit | Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"University of Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDONESIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Reconyl","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ University of Indonesia","highestDevelopmentStatusID":"8","companyTruncated":"Dexa Medica \/ University of Indonesia"},{"orgOrder":0,"company":"Regend Therapeutics","sponsor":"The First Affiliated Hospital of Guangzhou Medical University | Southwest Hospital | Shanghai Zhongshan Hospital | China-Japan Friendship Hospital | Shanghai East Hospital | Regend Therapeutics XLotus (Jiangxi) | The First Affiliated Hospital of Nanchang ","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGEND001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Regend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regend Therapeutics \/ The First Affiliated Hospital of Guangzhou Medical University | Southwest Hospital | Shanghai Zhongshan Hospital | China-Japan Friendship Hospital | Shanghai East Hospital | Regend Therapeutics XLotus (Jiangxi) | The First Affiliated Hospital of Nanchang ","highestDevelopmentStatusID":"8","companyTruncated":"Regend Therapeutics \/ The First Affiliated Hospital of Guangzhou Medical University | Southwest Hospital | Shanghai Zhongshan Hospital | China-Japan Friendship Hospital | Shanghai East Hospital | Regend Therapeutics XLotus (Jiangxi) | The First Affiliated Hospital of Nanchang "},{"orgOrder":0,"company":"Regend Therapeutics","sponsor":"Peking Union Medical College Hospital | RenJi Hospital | Ruijin Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"REGEND001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Regend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regend Therapeutics \/ Peking Union Medical College Hospital | RenJi Hospital | Ruijin Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Regend Therapeutics \/ Peking Union Medical College Hospital | RenJi Hospital | Ruijin Hospital"},{"orgOrder":0,"company":"Regend Therapeutics","sponsor":"Peking Union Medical College Hospital | Ruijin Hospital | The First Affiliated Hospital of Guangzhou Medical University | Regend Therapeutics XLotus (Jiangxi)","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGEND001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Regend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regend Therapeutics \/ Peking Union Medical College Hospital | Ruijin Hospital | The First Affiliated Hospital of Guangzhou Medical University | Regend Therapeutics XLotus (Jiangxi)","highestDevelopmentStatusID":"8","companyTruncated":"Regend Therapeutics \/ Peking Union Medical College Hospital | Ruijin Hospital | The First Affiliated Hospital of Guangzhou Medical University | Regend Therapeutics XLotus (Jiangxi)"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RSS0343","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Respivert","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"RV568","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivert","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respivert \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respivert \/ Undisclosed"},{"orgOrder":0,"company":"Respivert","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"RV568","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivert","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respivert \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respivert \/ Undisclosed"},{"orgOrder":0,"company":"Respivant Sciences","sponsor":"Respivant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"RVT-1601","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Respivant Sciences \/ Respivant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Respivant Sciences \/ Respivant Sciences"},{"orgOrder":0,"company":"SolAeroMed Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"S12268","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SolAeroMed Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"SolAeroMed Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SolAeroMed Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Sama pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"PALESTINE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SA09012","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sama pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sama pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sama pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SPARK Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SB17170","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SPARK Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPARK Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SPARK Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sensory Cloud","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SC0023","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sensory Cloud","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sensory Cloud \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensory Cloud \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-1703","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR-1703","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR-1905","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-1905","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR4597","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR4597","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Homeostasis||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SUN101","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Synvida Biotechnology Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SV001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Synvida Biotechnology Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Synvida Biotechnology Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Synvida Biotechnology Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Synvida Biotechnology Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SV001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Shanghai Synvida Biotechnology Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Synvida Biotechnology Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Synvida Biotechnology Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Taplucainium","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nocion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TEV-53275","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQ05105","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TQ05105","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQC2731","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQC2938","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Private Placement","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ Adage Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Adage Capital Partners"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ Avrobio","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Avrobio"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ Avrobio","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Avrobio"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ TAS Partners"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ TAS Partners"},{"orgOrder":0,"company":"Medipost","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Umbilical Cord Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medipost","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medipost \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medipost \/ Undisclosed"},{"orgOrder":0,"company":"Medipost","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Umbilical Cord Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medipost","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medipost \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medipost \/ Undisclosed"},{"orgOrder":0,"company":"Medipost","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Umbilical Cord Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medipost","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medipost \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medipost \/ Undisclosed"},{"orgOrder":0,"company":"Medipost","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Umbilical Cord Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medipost","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medipost \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medipost \/ Undisclosed"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"Amazentis","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Urolithin A","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University Health Centre Research Institute \/ Amazentis","highestDevelopmentStatusID":"8","companyTruncated":"McGill University Health Centre Research Institute \/ Amazentis"},{"orgOrder":0,"company":"Whanin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"WIN-901X","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Whanin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Whanin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Whanin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"PHARMENTERPRISES LLC","sponsor":"EURRUS Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PHARMENTERPRISES LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PHARMENTERPRISES LLC \/ EURRUS Biotech","highestDevelopmentStatusID":"8","companyTruncated":"PHARMENTERPRISES LLC \/ EURRUS Biotech"},{"orgOrder":0,"company":"PHARMENTERPRISES LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PHARMENTERPRISES LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PHARMENTERPRISES LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PHARMENTERPRISES LLC \/ Undisclosed"},{"orgOrder":0,"company":"Chemimmune Therapeutics","sponsor":"EURRUS Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chemimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chemimmune Therapeutics \/ EURRUS Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Chemimmune Therapeutics \/ EURRUS Biotech"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"YHD001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"YHD001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"YUNGJIN PHARM. CO. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"YPL-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"YUNGJIN PHARM. CO. LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YUNGJIN PHARM. CO. LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"YUNGJIN PHARM. CO. LTD \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"FLUIDDA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z7200","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ FLUIDDA","highestDevelopmentStatusID":"8","companyTruncated":"Zambon Switzerland \/ FLUIDDA"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z7200","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Z7200","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10383","moa":"Unknown","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10383","moa":"Unknown","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10383","moa":"Unknown","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Imperial College London","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Imperial College London \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Imperial College London \/ United Therapeutics"},{"orgOrder":0,"company":"University of Rochester","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Rochester \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of Rochester \/ United Therapeutics"},{"orgOrder":0,"company":"Xention Ltd","sponsor":"Ario Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"XEN-D0501","moa":"Vanilloid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xention Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xention Ltd \/ Ario Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Xention Ltd \/ Ario Pharma"},{"orgOrder":0,"company":"Xention Ltd","sponsor":"Ario Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"XEN-D0501","moa":"Vanilloid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xention Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xention Ltd \/ Ario Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Xention Ltd \/ Ario Pharma"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TEV-48574","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"Sichuan Cancer Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sichuan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sichuan Cancer Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Cancer Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Sichuan Cancer Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Sichuan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sichuan Cancer Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Cancer Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Novotech"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Seyltx","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Seyltx","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Seyltx"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biota Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biota Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biota Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biota Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Virtus Respiratory Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Virtus Respiratory Research","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Virtus Respiratory Research"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Sm04646","moa":"Wnt signalling pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"ClinResearch | Trio Clinical Research, LLC, Raleigh, USA | NuCara Pharmacy, Waterloo | Prof. Hochhaus, Gainesville, USA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ ClinResearch | Trio Clinical Research, LLC, Raleigh, USA | NuCara Pharmacy, Waterloo | Prof. Hochhaus, Gainesville, USA","highestDevelopmentStatusID":"8","companyTruncated":"Viatris \/ ClinResearch | Trio Clinical Research, LLC, Raleigh, USA | NuCara Pharmacy, Waterloo | Prof. Hochhaus, Gainesville, USA"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"University Hospital, Lille \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"VA Cooperative Studies Program | KAI Research | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Maryland, Baltimore \/ VA Cooperative Studies Program | KAI Research | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ VA Cooperative Studies Program | KAI Research | US Department of Defense"},{"orgOrder":0,"company":"ONY","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ONY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONY \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONY \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"QPS Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linvemastat","moa":"MMP-12","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ QPS Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ QPS Holdings"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-9813","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avalyn Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Expedition Therapeutics","sponsor":"Expedition Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"EXPD-101","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Expedition Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Expedition Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"Expedition Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GSK3862995B","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Meridian Bioscience","sponsor":"Ethan Weinberg","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"Bile acid receptor FXR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Meridian Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meridian Bioscience \/ Ethan Weinberg","highestDevelopmentStatusID":"8","companyTruncated":"Meridian Bioscience \/ Ethan Weinberg"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Bastiaan Driehuys","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Epoprostenol Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Bastiaan Driehuys","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ Bastiaan Driehuys"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Steven Hays, MD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"LAM-001","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"OrphAI Therapeutics \/ Steven Hays, MD","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI Therapeutics \/ Steven Hays, MD"},{"orgOrder":0,"company":"Genentech","sponsor":"Evans Fernandez Perez","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Evans Fernandez Perez","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Evans Fernandez Perez"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bastiaan Driehuys","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"129Xe-Hyperpolarized","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Bastiaan Driehuys","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Bastiaan Driehuys"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Juan Celedon","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Juan Celedon","highestDevelopmentStatusID":"8","companyTruncated":"Pharmavite \/ Juan Celedon"}]

    Find Drugs for Pulmonary/Respiratory Diseases in Phase II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Belumosudil in Children with Chronic Graft Versus Host Disease (schoolROCK)

                            Details : Belumosudil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Bronchiolitis Obliterans Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 11, 2025

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sanofi Expands Respiratory Pipeline with New Asthma, COPD Data

                            Details : SAR445229 (amlitelimab) is a fully human non-T cell depleting antibody that blocks OX40-Ligand, a key immune regulator, and has the potential to be a first- or best-in-class treatment for asthma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

                            Details : Lunsekimig is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 06, 2024

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere...

                            Details : Lunsekimig is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 24, 2024

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Par...

                            Details : Itepekimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bronchiectasis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 28, 2024

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe A...

                            Details : Lunsekimig is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 26, 2023

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-se...

                            Details : Amlitelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 13, 2023

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Na...

                            Details : Belumosudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bronchiolitis Obliterans Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 05, 2022

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

                            Details : Amlitelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 16, 2022

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

                            Details : Itepekimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 13, 2022

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth